- Home
- INKT vs GROW Comparison
INKT vs GROW Comparison
Compare INKT & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INKT | GROW |
|---|---|---|
| Founded | 2017 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 32.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | GROW |
|---|---|---|
| Price | $12.42 | $2.43 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 44.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $8,546,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $37.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.56 | $2.02 |
| 52 Week High | $76.00 | $2.78 |
Technical Indicators
Market Signals| Indicator | INKT | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 49.21 |
| Support Level | $11.48 | $2.36 |
| Resistance Level | $13.34 | $2.50 |
| Average True Range (ATR) | 0.84 | 0.08 |
| MACD | 0.27 | 0.01 |
| Stochastic Oscillator | 67.49 | 54.90 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.